ZURICH-SCHLIEREN, Switzerland, May 4, 2023 – DiNAQOR, an innovative genetic medicine company headquartered in Switzerland with subsidiaries in Laguna Hills/California/USA and Hamburg/Germany focused on proprietary

Chris Rusconi to serve as Chief Development Officer; Steven Zelenkofske to take role of Chief Strategy Officer as DiNAQOR continues rapid growth

Dinaqor is pleased to announce our participation in several fall conferences.

DiNAQOR announced the launch of DiNAQOR DiNAMIQS, a biomanufacturing subsidiary, that will accelerate development timelines and reduce costs and risk for genetic medicine companies bringing new treatments to market.

DiNAQOR has entered into a research collaboration with Children’s Medical Research Institute (CMRI) in Australia to develop novel bioengineered adeno-associated virus (AAV) capsids to route gene therapy directly to human cardiac muscle.

DiNAQOR has expanded its leadership team by appointing veteran medical device leader Mark Dehdashtian to serve as Executive Vice President, Medical Devices.

DiNAQOR has expanded the company’s board of directors with three new cardiovascular industry and academic experts: Louis G. Lange, M.D., Ph.D.; Steven Zelenkofske, D.O., M.S.; and Silke Rickert-Sperling, M.D.

DiNAQOR has acquired EHT Technologies GmbH, a Germany-based engineered heart tissue (EHT) technology platform company.

DiNAQOR announced that it will establish its own GMP manufacturing capabilities with a new 1200 sqm (13,000 sq. ft) GMP facility in the Bio-Technopark Schlieren-Zürich

DiNAQOR CEO Johannes Holzmeister discusses the company’s innovative gene therapy platform, recent partnerships and how DiNAQOR is uniquely positioned to deliver successful treatments for patient’s suffering from heart failure with Nature Research.

DiNAQOR CSO Thomas Voit discusses trends in cardiovascular gene therapy and the company’s partnership with BioMarin with Nature Research.

DiNAQOR announced that Eduard Ayuso, D.V.M., Ph.D. has been appointed as Chief Technology Officer.

DiNAQOR announced the expansion of its global research and development operations with a new facility in the Bio-Technopark Schlieren-Zürich.

BioMarin Pharmaceutical has entered into a preclinical collaboration and license agreement with DiNAQOR to develop novel gene therapies to treat rare genetic cardiomyopathies.

DiNAQOR today announced a research collaboration and exclusive license agreement with UCL to develop novel gene therapies for the treatment of monogenic cardiomyopathies